genedrive PLC (LON:GDR) said data from an 11-month study of its molecular diagnostic device in neonatal intensive care will be ready in early 2021.
Hospitals in Manchester and Liverpool used the assay to screen babies before administering certain antibiotics known to cause deafness.
In all, around 750 infants were assessed using the MT-RNR1 ID kit.
The company said it was now working with the study team as well as commercial partner, Inspiration Healthcare, ahead of the commercial roll-out.
The full launch is expected to take place next June following the inclusion of feedback from the trial sites.
"The completion of the AIHL study is an important milestone in the development and commercialisation of our novel test,” said genedrive chief executive, David Budd in a statement.
“We have developed a unique assay with compelling health economic benefits which can provide a clinically actionable result in a relevant timeframe, and ultimately could positively alter the lives of thousands of babies every year."
